基质金属蛋白酶抑制剂的酶激活。
Enzymatic activation of a matrix metalloproteinase inhibitor.
机构信息
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0358, USA.
出版信息
Chem Commun (Camb). 2010 Feb 28;46(8):1241-3. doi: 10.1039/b923302d. Epub 2010 Jan 18.
Abstract
Matrix metalloproteinase inhibitors (MMPi) possessing a glucose protecting group on the zinc-binding group (ZBG) show a dramatic increase in inhibitory activity upon cleavage by beta-glucosidase.
摘要
基质金属蛋白酶抑制剂（MMPi）在锌结合基团（ZBG）上带有葡萄糖保护基团，在被β-葡萄糖苷酶切割时，其抑制活性会显著增加。
相似文献
1
Enzymatic activation of a matrix metalloproteinase inhibitor.
Chem Commun (Camb). 2010 Feb 28;46(8):1241-3. doi: 10.1039/b923302d. Epub 2010 Jan 18.
2
Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide.
J Biol Inorg Chem. 2011 Feb;16(2):313-23. doi: 10.1007/s00775-010-0727-x. Epub 2010 Nov 4.
3
Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
Bioorg Med Chem Lett. 2009 Apr 1;19(7):1970-6. doi: 10.1016/j.bmcl.2009.02.044. Epub 2009 Feb 14.
4
Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.
Chem Commun (Camb). 2011 Jul 28;47(28):7968-70. doi: 10.1039/c1cc12526e. Epub 2011 Jun 16.
5
Role of sulfonamide group in matrix metalloproteinase inhibitors.
Curr Med Chem. 2008;15(4):368-73. doi: 10.2174/092986708783497300.
6
Progress in the development of matrix metalloproteinase inhibitors.
Curr Med Chem. 2008;15(14):1388-95. doi: 10.2174/092986708784567680.
7
Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.
J Biol Inorg Chem. 2004 Apr;9(3):307-15. doi: 10.1007/s00775-004-0524-5. Epub 2004 Feb 5.
8
Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Biochem J. 2005 Dec 15;392(Pt 3):527-36. doi: 10.1042/BJ20050545.
9
Zinc-binding groups modulate selective inhibition of MMPs.
ChemMedChem. 2008 May;3(5):812-20. doi: 10.1002/cmdc.200700290.
10
Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction.
J Mol Graph Model. 2003 Nov;22(2):115-26. doi: 10.1016/S1093-3263(03)00153-0.
引用本文的文献
1
Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.
RSC Med Chem. 2022 Jul 29;13(10):1127-1149. doi: 10.1039/d2md00175f. eCollection 2022 Oct 19.
2
Evaluating prodrug strategies for esterase-triggered release of alcohols.
ChemMedChem. 2013 Oct;8(10):1662-7. doi: 10.1002/cmdc.201300255. Epub 2013 Aug 8.
3
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.
Molecules. 2012 Mar 26;17(4):3672-89. doi: 10.3390/molecules17043672.
4
Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.
Chem Commun (Camb). 2011 Jul 28;47(28):7968-70. doi: 10.1039/c1cc12526e. Epub 2011 Jun 16.
5
Emerging trends in metalloprotein inhibition.
Dalton Trans. 2011 Apr 14;40(14):3445-54. doi: 10.1039/c0dt01743d. Epub 2011 Feb 2.
6
Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide.
J Biol Inorg Chem. 2011 Feb;16(2):313-23. doi: 10.1007/s00775-010-0727-x. Epub 2010 Nov 4.
7
Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approach.
Angew Chem Int Ed Engl. 2010 Sep 10;49(38):6795-7. doi: 10.1002/anie.201003819.
本文引用的文献
1
A two-photon tracer for glucose uptake.
Angew Chem Int Ed Engl. 2009;48(43):8027-31. doi: 10.1002/anie.200901175.
2
Targeting: the ADEPT story so far.
Curr Drug Targets. 2009 Feb;10(2):152-7. doi: 10.2174/138945009787354520.
3
Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
J Med Chem. 2009 Jan 22;52(2):537-43. doi: 10.1021/jm8009102.
4
Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
J Med Chem. 2008 Dec 11;51(23):7428-41. doi: 10.1021/jm8006257.
5
Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease.
Dalton Trans. 2008 Dec 7(45):6364-7. doi: 10.1039/b815404j. Epub 2008 Oct 6.
6
Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.
Bioorg Med Chem. 2008 Sep 1;16(17):8109-16. doi: 10.1016/j.bmc.2008.07.048. Epub 2008 Jul 23.
7
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.
J Am Chem Soc. 2008 Aug 20;130(33):11219-22. doi: 10.1021/ja8033763. Epub 2008 Jul 19.
8
Causes and consequences of increased glucose metabolism of cancers.
J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S. doi: 10.2967/jnumed.107.047258.
9
Zinc-binding groups modulate selective inhibition of MMPs.
ChemMedChem. 2008 May;3(5):812-20. doi: 10.1002/cmdc.200700290.
10
Painting the target around the arrow: two-step prodrug therapies from a carbohydrate chemist's perspective.
Curr Drug Deliv. 2007 Oct;4(4):264-8. doi: 10.2174/156720107782151278.
Zotero 插件